roflumilast


Also found in: Medical, Wikipedia.
Related to roflumilast: indacaterol, PDE4 inhibitor
Translations

roflumilast

n roflumilast m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
The guideline addresses the use of numerous medications, alone or in combination, including short- and long-acting beta-2 agonists, short- and long-acting muscarinic antagonists, inhaled corticosteroids, inhaled long-acting anticholinergics, long-term macrolides, oral and IV systemic corticosteroids, roflumilast (when chronic bronchitis is present), oral slow-release theophylline, oral N-acetylcysteine, oral carbocysteine, and statins.
Phosphodiesterase 4 inhibitors such as roflumilast have been shown to inhibit the release of several inflammatory cytokines and chemokines in LPS-stimulated macrophages.
Upon completion of the transaction, AstraZeneca will own the development and commercial rights to Tudorza Pressair (aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD), and Daliresp (roflumilast), a once-daily oral PDE4 inhibitor currently on the market for COPD.
AstraZeneca owns the development and commercial rights in the US and Canada to Tudorza Pressair (aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist for chronic obstructive pulmonary disease, and to Daliresp (roflumilast), the only once-daily oral PDE4 inhibitor currently on the market for COPD, in the US.
Additionally, AstraZeneca will own the development and commercial rights in the US and Canada Daliresp (roflumilast), the only once-daily oral PDE4 inhibitor currently on the market for COPD.
Kumar, "Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma," Clinical and Experimental Allergy, vol.
Specific therapy for the reduction of exacerbations includes the addition of a phosphodiesterase-4 inhibitor, roflumilast. It has recently been registered in South Africa for the treatment of severe COPD associated with chronic bronchitis and a history of frequent exacerbations.
Selective phosphodiesterase inhibitors such as roflumilast are not registered for use in acute asthma.
Many drugs with enhanced effectiveness and selectivity contain the C[F.sub.3]O moiety (e.g., celikalim, roflumilast and riluzole) (Figure 1).
This edition includes new drugs, including Azilsartan Medoxomil, Boceprevir, Clobazam, Ezogabine, Fidaxomicin, Linagliptin, Rilpivirine, Rivaroxaban, Telaprevir, Roflumilast, Ticagrelor, and Vilazodone; updated bisphosphonate, antipsychotic, carbapenem, and proton pump inhibitor group monographs; new combinations such as Emtricitabine/Rilpivirine/Tenofovir; and a revised ophthalmic/otic chapter with additions like glaucoma combinations, mast cell stabilizers, ophthalmic antihistamines, and otic corticosteroids.
One PDE4 inhibitor called roflumilast has already been approved by FDA for the treatment of COPD (chronic obstructive pulmonary disease).